中電信(00728.HK)擬發行最多120.93億股A股於上交所主板上市
中國電信(00728.HK)擬申請發行A股並在上交所主板上市,發行A股數量不超過120.93億股,不超過A股發行後、超額配售選擇權行使前已發行總股本的13%。
在符合法規及監管要求下,中電信可在本次A股發行時實施戰略配售。在是次A股發行完成及倘超額配售權獲悉數行使,H股股東持股比例料將由17.15%下降至14.63%。
公司表示,申請A股上市將把握數字化發展機遇,完善公司治理,拓寬融資渠道,加快改革發展,推動戰略落地,實現高質量發展。決議案已於今日(9日)經董事會審議通過,將提請股東會議審議批准。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.